RxDoctor Payments Data

Brian Casaclang, DO

Family Medicine · Chicago, ILNPI 1093740490

Payments from drug & device makers

$783in general payments, 2019–2025

Across 31 payments — averaging $25.26 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$534
  • Merck$84
  • Pfizer$47
  • Lilly USA, LLC$45
  • Exact Sciences$19
  • Abbott$16
  • plus $38 from 3 others

What the payments were for

  • Food & beverage$65484%
  • Education$12916%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$783 in reported general payments places this provider in the 70th percentile of 4,116 family medicine providers in Illinois.

See all family medicine providers in Illinois

Medicare billing

Part B allowed, 2024
$59,083
Medicare patients
174
Services billed
1,136

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide63$83,721
JardianceEmpagliflozin24$35,548
EliquisApixaban17$20,417
JanuviaSitagliptin Phosphate12$19,050
Breo ElliptaFluticasone/Vilanterol23$16,598
Advair HfaFluticasone Propion/Salmeterol14$13,909
Testosterone67$11,770
Omega-3 Acid Ethyl Esters22$4,845
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$4,125
Atorvastatin Calcium182$4,099
Montelukast Sodium91$3,608
Azelastine-FluticasoneAzelastine/Fluticasone11$2,907
Pravastatin Sodium63$2,299
Tamsulosin Hcl62$2,188
Pioglitazone Hcl53$2,064

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$534$83,72163 claims
PfizerEliquis$47$20,41717 claims
MerckJanuvia$84$19,05012 claims
GSKBreo Ellipta$13$16,59823 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,116 family medicine providers in Illinois.

Other family medicine in Chicago

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →